Agno Pharmaceuticals is a global small molecule CDMO supplying critical RSMs, intermediates, active pharmaceutical ingredients (APIs), highly potent APIs, sterile APIs, and sterile drug product formulations to large and medium-sized pharmaceutical, biotech, generic and CDMO customers. Founded in 2004, Agno has process development and US-FDA inspected GMP-compliant manufacturing facilities with sterile suspension injectable manufacturing capabilities. In addition, Agno has established a drug product formulation research and development laboratory for complex injectables. Agno Pharmaceuticals has invested in its people and facilities and established a broad spectrum of service capabilities throughout the entire drug development and commercialization process. Agno Pharmaceuticals has an excellent track record in the delivery of both development and commercial stage cGMP manufacturing solutions to its customers in North America and Europe.